The rare disease revolution: The state of play for CGTs in orphan diseases
Cell and gene therapies are fuelling new possibilities for rare diseases, turning a field defined by unmet need into one of the industry’s most dynamic areas of innovation.
Sponsored
Develop site-centric protocols to optimize enrollment and maximize performance
Remedying the paper trail: Manufacturing a digital route to compliance
How to avoid common contamination control mistakes in new aseptic facilities
Why CMC readiness is becoming central to biopharma licensing deals
Formulation as a key differentiator in crowded therapeutic areas
Asia’s clinical research revolution: Why the world’s innovation centre is shifting east
Reaching maturity: A roadmap for Quality Excellence amid regulatory transformation
